Myelofibrosis
Clinical trials for Myelofibrosis explained in plain language.
Never miss a new study
Get alerted when new Myelofibrosis trials appear
Sign up with your email to follow new studies for Myelofibrosis, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for myelofibrosis patients: experimental drug RVU120 enters Mid-Stage trial
Disease control Stopped earlyThis Phase 2 trial tests a new drug called RVU120, alone or with the standard drug ruxolitinib, in 230 adults with intermediate or high-risk myelofibrosis. The main goal is to see if the drug can shrink the spleen and improve symptoms. Participants must have not responded well to…
Matched conditions: MYELOFIBROSIS
Phase 2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Rollover study offers continued itacitinib access for chronic disease patients
Disease control Stopped earlyThis study provides continued access to itacitinib for 18 patients who were already benefiting from the drug in earlier trials. Participants have myelofibrosis, chronic graft-versus-host disease, or bronchiolitis obliterans after lung transplant. They continue their same dose as …
Matched conditions: MYELOFIBROSIS
Phase 2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Cord blood transplant trial for blood cancers halted early
Disease control Stopped earlyThis study looked at using umbilical cord blood transplants after strong chemotherapy and radiation to treat various blood cancers like leukemia and lymphoma. It involved 200 participants and aimed to see how many were alive one year after transplant. The trial was stopped early,…
Matched conditions: MYELOFIBROSIS
Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Experimental combo for rare blood cancer shows promise but trial halted early
Disease control Stopped earlyThis early-phase trial tested a combination of two drugs—ruxolitinib and CPX-351—in 12 people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. The goal was to find the best dose and see if the combo could shrink cancer. However, the study was stop…
Matched conditions: MYELOFIBROSIS
Phase 1/2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo for rare bone marrow cancer shows early promise, but trial halted
Disease control Stopped earlyThis study tested two experimental drugs, TQ05105 and TQB3909, taken together as tablets for people with moderate- to high-risk myelofibrosis, a rare bone marrow disorder. The goal was to see if the combination could shrink an enlarged spleen and improve symptoms. The trial enrol…
Matched conditions: MYELOFIBROSIS
Phase 1/2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Cancer drug trial halted early: what we know
Disease control Stopped earlyThis study tested a new drug called INCB059872 in people with advanced solid tumors or blood cancers that had not responded to standard treatments. The goal was to find a safe dose and see if it could control the disease. The trial was stopped early, so results are limited.
Matched conditions: MYELOFIBROSIS
Phase 1/2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Myelofibrosis drug combo trial ends early – what it means
Disease control Stopped earlyThis phase 3 trial tested whether adding parsaclisib to the standard drug ruxolitinib could better shrink the spleen and ease symptoms in people with myelofibrosis. The study enrolled 252 participants but was terminated early, so the full results are not available. The goal was t…
Matched conditions: MYELOFIBROSIS
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New combo therapy aims to shrink spleen and ease symptoms in hard-to-treat myelofibrosis
Disease control Stopped earlyThis study tested whether adding the experimental drug parsaclisib to the standard drug ruxolitinib helps people with myelofibrosis whose spleen and symptoms haven't improved enough on ruxolitinib alone. The main goal was to see if the combination could shrink the spleen by at le…
Matched conditions: MYELOFIBROSIS
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC